|
EP2734621B1
(en)
|
2011-07-22 |
2019-09-04 |
President and Fellows of Harvard College |
Evaluation and improvement of nuclease cleavage specificity
|
|
ES2731524T3
(es)
|
2012-04-05 |
2019-11-15 |
Massachusetts Inst Technology |
Composiciones inmunoestimuladoras y métodos de uso de las mismas
|
|
EP3653212B1
(en)
|
2012-12-20 |
2023-04-26 |
Purdue Research Foundation |
Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
|
|
BR112015027567B1
(pt)
|
2013-05-03 |
2024-02-20 |
Ohio State Innovation Foundation |
Polipeptídeo, sequência de ácido nucleico isolada, vetor, método de obtenção de célula, uso de uma célula
|
|
US9163284B2
(en)
|
2013-08-09 |
2015-10-20 |
President And Fellows Of Harvard College |
Methods for identifying a target site of a Cas9 nuclease
|
|
US9359599B2
(en)
|
2013-08-22 |
2016-06-07 |
President And Fellows Of Harvard College |
Engineered transcription activator-like effector (TALE) domains and uses thereof
|
|
US9526784B2
(en)
|
2013-09-06 |
2016-12-27 |
President And Fellows Of Harvard College |
Delivery system for functional nucleases
|
|
US9322037B2
(en)
|
2013-09-06 |
2016-04-26 |
President And Fellows Of Harvard College |
Cas9-FokI fusion proteins and uses thereof
|
|
US9340800B2
(en)
|
2013-09-06 |
2016-05-17 |
President And Fellows Of Harvard College |
Extended DNA-sensing GRNAS
|
|
EP3057994B1
(en)
|
2013-10-15 |
2020-09-23 |
The Scripps Research Institute |
Peptidic chimeric antigen receptor t cell switches and uses thereof
|
|
EP3057991B8
(en)
*
|
2013-10-15 |
2019-09-04 |
The Scripps Research Institute |
Chimeric antigen receptor t cell switches and uses thereof
|
|
US20150165054A1
(en)
|
2013-12-12 |
2015-06-18 |
President And Fellows Of Harvard College |
Methods for correcting caspase-9 point mutations
|
|
GB201409558D0
(en)
|
2014-05-29 |
2014-07-16 |
Ucb Biopharma Sprl |
Method
|
|
GB201412658D0
(en)
|
2014-07-16 |
2014-08-27 |
Ucb Biopharma Sprl |
Molecules
|
|
GB201412659D0
(en)
|
2014-07-16 |
2014-08-27 |
Ucb Biopharma Sprl |
Molecules
|
|
CA2956224A1
(en)
|
2014-07-30 |
2016-02-11 |
President And Fellows Of Harvard College |
Cas9 proteins including ligand-dependent inteins
|
|
ES2688035T3
(es)
|
2014-08-29 |
2018-10-30 |
Gemoab Monoclonals Gmbh |
Receptor de antígeno universal que expresa células inmunes para direccionamiento de antígenos múltiples diversos, procedimiento para fabricación del mismo y utilización del mismo para tratamiento de cáncer, infecciones y enfermedades autoinmunes
|
|
KR102606190B1
(ko)
|
2015-02-20 |
2023-11-23 |
오하이오 스테이트 이노베이션 파운데이션 |
Nkg2d 및 종양 연관 항원에 대해 유도된 이가 항체
|
|
US9777064B2
(en)
|
2015-03-17 |
2017-10-03 |
Chimera Bioengineering, Inc. |
Smart CAR devices, DE CAR polypeptides, side CARs and uses thereof
|
|
WO2016154621A1
(en)
*
|
2015-03-26 |
2016-09-29 |
The California Institute For Biomedical Research |
SWITCHABLE NON-scFv CHIMERIC RECEPTORS, SWITCHES, AND USES THEREOF
|
|
JP6879932B2
(ja)
|
2015-04-06 |
2021-06-02 |
サイトイミューン セラピューティクス， インコーポレイテッドＣｙｔｏｉｍｍｕｎｅ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｌｌｃ |
神経膠芽腫のためのｅｇｆｒ指向ｃａｒ療法
|
|
EP3283113A4
(en)
*
|
2015-04-15 |
2018-12-05 |
The California Institute for Biomedical Research |
Optimized pne-based chimeric receptor t cell switches and uses thereof
|
|
US10676723B2
(en)
|
2015-05-11 |
2020-06-09 |
David Gordon Bermudes |
Chimeric protein toxins for expression by therapeutic bacteria
|
|
MX2017014822A
(es)
|
2015-05-18 |
2018-04-30 |
Tcr2 Therapeutics Inc |
Composiciones y métodos para la reprogramación del tcr con proteínas de fusión.
|
|
GB201601077D0
(en)
|
2016-01-20 |
2016-03-02 |
Ucb Biopharma Sprl |
Antibody molecule
|
|
GB201601075D0
(en)
|
2016-01-20 |
2016-03-02 |
Ucb Biopharma Sprl |
Antibodies molecules
|
|
GB201601073D0
(en)
|
2016-01-20 |
2016-03-02 |
Ucb Biopharma Sprl |
Antibodies
|
|
CN117964732A
(zh)
*
|
2015-08-07 |
2024-05-03 |
Alx肿瘤生物技术公司 |
具有SIRP-α结构域或其变体的构建体
|
|
KR20180053744A
(ko)
|
2015-09-23 |
2018-05-23 |
사이토이뮨 테라퓨틱스 엘엘씨 |
면역 요법을 위한 flt3 유도된 car 세포
|
|
WO2017069958A2
(en)
|
2015-10-09 |
2017-04-27 |
The Brigham And Women's Hospital, Inc. |
Modulation of novel immune checkpoint targets
|
|
EP4434589A3
(en)
|
2015-10-23 |
2025-05-14 |
President and Fellows of Harvard College |
Evolved cas9 proteins for gene editing
|
|
WO2017075451A1
(en)
|
2015-10-28 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1
|
|
WO2017075465A1
(en)
|
2015-10-28 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3
|
|
WO2017075537A1
(en)
*
|
2015-10-30 |
2017-05-04 |
Aleta Biotherapeutics Inc. |
Compositions and methods for treatment of cancer
|
|
CN108472365A
(zh)
|
2015-10-30 |
2018-08-31 |
艾丽塔生物治疗剂公司 |
用于肿瘤转导的组合物和方法
|
|
PT3377103T
(pt)
*
|
2015-11-19 |
2021-05-26 |
Revitope Ltd |
Complementação de fragmento de anticorpo funcional para um sistema de dois componentes para exterminação redirecionada de células indesejadas
|
|
WO2017087708A1
(en)
|
2015-11-19 |
2017-05-26 |
The Brigham And Women's Hospital, Inc. |
Lymphocyte antigen cd5-like (cd5l)-interleukin 12b (p40) heterodimers in immunity
|
|
GB201521393D0
(en)
*
|
2015-12-03 |
2016-01-20 |
Ucb Biopharma Sprl |
Antibodies
|
|
GB201521383D0
(en)
*
|
2015-12-03 |
2016-01-20 |
Ucb Biopharma Sprl And Ucb Celltech |
Method
|
|
GB201521391D0
(en)
|
2015-12-03 |
2016-01-20 |
Ucb Biopharma Sprl |
Antibodies
|
|
GB201521389D0
(en)
|
2015-12-03 |
2016-01-20 |
Ucb Biopharma Sprl |
Method
|
|
GB201521382D0
(en)
*
|
2015-12-03 |
2016-01-20 |
Ucb Biopharma Sprl |
Antibodies
|
|
US11052111B2
(en)
|
2015-12-08 |
2021-07-06 |
Chimera Bioengineering, Inc. |
Smart CAR devices and DE CAR polypeptides for treating disease and methods for enhancing immune responses
|
|
GB201602974D0
(en)
*
|
2016-02-19 |
2016-04-06 |
Clube Jasper R |
Engineered cells & methods (1)
|
|
EP3439675A4
(en)
|
2016-04-08 |
2019-12-18 |
Purdue Research Foundation |
METHOD AND COMPOSITIONS FOR CAR-T CELL THERAPY
|
|
WO2017180587A2
(en)
|
2016-04-11 |
2017-10-19 |
Obsidian Therapeutics, Inc. |
Regulated biocircuit systems
|
|
WO2017201019A1
(en)
|
2016-05-17 |
2017-11-23 |
Chimera Bioengineering, Inc. |
Methods for making novel antigen binding domains
|
|
KR102223822B1
(ko)
*
|
2016-07-12 |
2021-03-11 |
카이트 파마 인코포레이티드 |
항원 결합 분자 및 그의 사용 방법
|
|
CA3032498A1
(en)
|
2016-08-02 |
2018-02-08 |
TCR2 Therapeutics Inc. |
Compositions and methods for tcr reprogramming using fusion proteins
|
|
JP7231935B2
(ja)
|
2016-08-03 |
2023-03-08 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
アデノシン核酸塩基編集因子およびそれらの使用
|
|
US11661590B2
(en)
|
2016-08-09 |
2023-05-30 |
President And Fellows Of Harvard College |
Programmable CAS9-recombinase fusion proteins and uses thereof
|
|
WO2018039438A1
(en)
|
2016-08-24 |
2018-03-01 |
President And Fellows Of Harvard College |
Incorporation of unnatural amino acids into proteins using base editing
|
|
EP3858365B1
(en)
*
|
2016-09-01 |
2024-01-31 |
Chimera Bioengineering Inc. |
Gold optimized car t-cells
|
|
WO2018049025A2
(en)
|
2016-09-07 |
2018-03-15 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses
|
|
IL265438B2
(en)
*
|
2016-09-23 |
2023-10-01 |
Univ Southern California |
Chimeric antigen receptors and compositions and methods of use thereof
|
|
MX2019003899A
(es)
|
2016-10-07 |
2019-08-14 |
Tcr2 Therapeutics Inc |
Composiciones y metodos para reprogramacion de receptores de linfocitos t mediante el uso de proteinas de fusion.
|
|
WO2018067991A1
(en)
|
2016-10-07 |
2018-04-12 |
The Brigham And Women's Hospital, Inc. |
Modulation of novel immune checkpoint targets
|
|
AU2017342543B2
(en)
|
2016-10-14 |
2024-06-27 |
President And Fellows Of Harvard College |
AAV delivery of nucleobase editors
|
|
WO2018075807A1
(en)
*
|
2016-10-19 |
2018-04-26 |
California Institute For Biomedical Research |
Chimeric antigen receptor effector cell switches with humanized targeting moieties and/or optimized chimeric antigen receptor interacting domains and uses thereof
|
|
EP3315511A1
(en)
|
2016-10-29 |
2018-05-02 |
Miltenyi Biotec GmbH |
Adapter chimeric antigen receptor expressing cells for targeting of multiple antigens
|
|
CN108018299B
(zh)
*
|
2016-11-01 |
2020-03-17 |
上海恒润达生生物科技有限公司 |
靶向bcma的嵌合抗原受体及其用途
|
|
EP3565555A4
(en)
|
2016-11-07 |
2021-03-17 |
VIDAC Pharma Ltd. |
USE OF HEXKINASE-2 / MITOCHONDRIAL DISCONNECTORS FOR TREATMENT OF HEXKINASE-2 (HC2) EXPRESSING CANCER DISEASES
|
|
US10682346B2
(en)
|
2016-11-07 |
2020-06-16 |
Vidac Pharma Ltd. |
Use of hexokinase 2/mitochondria-detaching compounds for activating immune responses
|
|
US12227578B2
(en)
|
2016-11-11 |
2025-02-18 |
The Broad Institute, Inc. |
Modulation of intestinal epithelial cell differentiation, maintenance and/or function through T cell action
|
|
EP3544996A2
(en)
|
2016-11-22 |
2019-10-02 |
TCR2 Therapeutics Inc. |
Compositions and methods for tcr reprogramming using fusion proteins
|
|
US11180535B1
(en)
|
2016-12-07 |
2021-11-23 |
David Gordon Bermudes |
Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
|
|
CN107058315B
(zh)
*
|
2016-12-08 |
2019-11-08 |
上海优卡迪生物医药科技有限公司 |
敲减人PD-1的siRNA、重组表达CAR-T载体及其构建方法和应用
|
|
US11242402B2
(en)
|
2016-12-23 |
2022-02-08 |
Macrogenics, Inc. |
ADAM9-binding molecules, and methods of use thereof
|
|
WO2018119359A1
(en)
|
2016-12-23 |
2018-06-28 |
President And Fellows Of Harvard College |
Editing of ccr5 receptor gene to protect against hiv infection
|
|
CN110121505B
(zh)
|
2016-12-28 |
2023-08-01 |
株式会社绿十字细胞治疗 |
嵌合抗原受体和表达其的自然杀伤细胞
|
|
US11649288B2
(en)
|
2017-02-07 |
2023-05-16 |
Seattle Children's Hospital |
Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents
|
|
PE20191716A1
(es)
|
2017-02-08 |
2019-12-05 |
Bristol Myers Squibb Co |
Polipeptidos de relaxina modificada que comprenden un mejorador farmacocinetico y sus usos
|
|
CN110582298A
(zh)
*
|
2017-02-17 |
2019-12-17 |
优努姆治疗公司 |
抗bcma抗体和抗体偶联t细胞受体(actr)在癌症治疗和b细胞疾病中的联合使用
|
|
ES3010559T3
(en)
|
2017-02-28 |
2025-04-03 |
Endocyte Inc |
Compositions and methods for car t cell therapy
|
|
JP7341900B2
(ja)
*
|
2017-03-03 |
2023-09-11 |
オブシディアン セラピューティクス， インコーポレイテッド |
免疫療法のためのｃｄ１９組成物及び方法
|
|
US11629340B2
(en)
|
2017-03-03 |
2023-04-18 |
Obsidian Therapeutics, Inc. |
DHFR tunable protein regulation
|
|
CN110662556A
(zh)
|
2017-03-09 |
2020-01-07 |
哈佛大学的校长及成员们 |
癌症疫苗
|
|
US11898179B2
(en)
|
2017-03-09 |
2024-02-13 |
President And Fellows Of Harvard College |
Suppression of pain by gene editing
|
|
JP2020510439A
(ja)
|
2017-03-10 |
2020-04-09 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
シトシンからグアニンへの塩基編集因子
|
|
WO2018176009A1
(en)
|
2017-03-23 |
2018-09-27 |
President And Fellows Of Harvard College |
Nucleobase editors comprising nucleic acid programmable dna binding proteins
|
|
US11963966B2
(en)
|
2017-03-31 |
2024-04-23 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for treating ovarian tumors
|
|
US11913075B2
(en)
|
2017-04-01 |
2024-02-27 |
The Broad Institute, Inc. |
Methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer
|
|
WO2018191553A1
(en)
|
2017-04-12 |
2018-10-18 |
Massachusetts Eye And Ear Infirmary |
Tumor signature for metastasis, compositions of matter methods of use thereof
|
|
JP2020517259A
(ja)
|
2017-04-19 |
2020-06-18 |
ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム |
操作された抗原受容体を発現する免疫細胞
|
|
US12226479B2
(en)
|
2017-05-11 |
2025-02-18 |
The General Hospital Corporation |
Methods and compositions of use of CD8+ tumor infiltrating lymphocyte subtypes and gene signatures thereof
|
|
US11560566B2
(en)
|
2017-05-12 |
2023-01-24 |
President And Fellows Of Harvard College |
Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation
|
|
WO2018232195A1
(en)
|
2017-06-14 |
2018-12-20 |
The Broad Institute, Inc. |
Compositions and methods targeting complement component 3 for inhibiting tumor growth
|
|
WO2019014581A1
(en)
|
2017-07-14 |
2019-01-17 |
The Broad Institute, Inc. |
METHODS AND COMPOSITIONS FOR MODULATING THE ACTIVITY OF A CYTOTOXIC LYMPHOCYTE
|
|
US11732274B2
(en)
|
2017-07-28 |
2023-08-22 |
President And Fellows Of Harvard College |
Methods and compositions for evolving base editors using phage-assisted continuous evolution (PACE)
|
|
WO2019139645A2
(en)
|
2017-08-30 |
2019-07-18 |
President And Fellows Of Harvard College |
High efficiency base editors comprising gam
|
|
CA3076337A1
(en)
*
|
2017-09-19 |
2019-03-28 |
Massachusetts Institute Of Technology |
Compositions for chimeric antigen receptor t cell therapy and uses thereof
|
|
US12043870B2
(en)
|
2017-10-02 |
2024-07-23 |
The Broad Institute, Inc. |
Methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer
|
|
KR20200121782A
(ko)
|
2017-10-16 |
2020-10-26 |
더 브로드 인스티튜트, 인코퍼레이티드 |
아데노신 염기 편집제의 용도
|
|
WO2019084055A1
(en)
|
2017-10-23 |
2019-05-02 |
Massachusetts Institute Of Technology |
CLASSIFICATION OF GENETIC VARIATION FROM UNICELLULAR TRANSCRIPTOMS
|
|
US11117936B2
(en)
|
2017-11-10 |
2021-09-14 |
University of Pittsburg—Of the Commonwealth System of Higher Education |
Affinity-enhanced monomeric streptavidin chimeric antigen receptor (CAR)
|
|
EP3710039A4
(en)
|
2017-11-13 |
2021-08-04 |
The Broad Institute, Inc. |
METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER BY TARGETING THE CLEC2D-KLRB1 PATH
|
|
US12171783B2
(en)
|
2017-11-13 |
2024-12-24 |
The Broad Institute, Inc. |
Methods and compositions for targeting developmental and oncogenic programs in H3K27M gliomas
|
|
US11649294B2
(en)
|
2017-11-14 |
2023-05-16 |
GC Cell Corporation |
Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same
|
|
AU2018370195B2
(en)
|
2017-11-14 |
2022-01-13 |
Green Cross Lab Cell Corporation |
Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same
|
|
US12406749B2
(en)
|
2017-12-15 |
2025-09-02 |
The Broad Institute, Inc. |
Systems and methods for predicting repair outcomes in genetic engineering
|
|
JP6981234B2
(ja)
*
|
2017-12-22 |
2021-12-15 |
住友電装株式会社 |
バッテリターミナルカバー
|
|
US11994512B2
(en)
|
2018-01-04 |
2024-05-28 |
Massachusetts Institute Of Technology |
Single-cell genomic methods to generate ex vivo cell systems that recapitulate in vivo biology with improved fidelity
|
|
AU2019209428B2
(en)
|
2018-01-22 |
2025-06-26 |
Endocyte, Inc. |
Methods of use for CAR T cells
|
|
CA3090089A1
(en)
|
2018-02-06 |
2019-08-15 |
Seattle Children's Hospital (dba Seattle Children's Research Institute) |
Fluorescein-specific cars exhibiting optimal t cell function against fl-ple labelled tumors
|
|
US11110125B2
(en)
|
2018-02-13 |
2021-09-07 |
Chimera Bioengineering, Inc. |
Coordinating gene expression using RNA destabilizing elements
|
|
JP7273421B2
(ja)
|
2018-02-21 |
2023-05-15 |
ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム |
ナチュラルキラー細胞の活性化および拡大のための方法ならびにその使用
|
|
TW202000229A
(zh)
|
2018-02-23 |
2020-01-01 |
美商安德賽特公司 |
Car t細胞療法之順序方法
|
|
WO2019168923A1
(en)
|
2018-03-01 |
2019-09-06 |
University Of Kansas |
Techniques for generating cell-based therapeutics using recombinant t cell receptor genes
|
|
AU2019249215B2
(en)
|
2018-04-06 |
2026-02-19 |
The Regents Of The University Of California |
Methods of treating EGFRvIII expressing glioblastomas
|
|
EP3773633A4
(en)
|
2018-04-06 |
2022-01-26 |
The Regents of The University of California |
METHODS OF TREATMENT OF GLIOBLASTOMA
|
|
WO2019203600A1
(ko)
*
|
2018-04-18 |
2019-10-24 |
앱클론(주) |
스위치 분자 및 스위처블 키메라 항원 수용체
|
|
EP3561053A1
(en)
*
|
2018-04-26 |
2019-10-30 |
Baylor College of Medicine |
Immune effector cells and molecular adaptors with an antigen cytokine complex for effective cancer immunotherapy
|
|
US11957695B2
(en)
|
2018-04-26 |
2024-04-16 |
The Broad Institute, Inc. |
Methods and compositions targeting glucocorticoid signaling for modulating immune responses
|
|
WO2019222579A1
(en)
*
|
2018-05-17 |
2019-11-21 |
St. Jude Children's Research Hospital, Inc. |
Chimeric antigen receptors with myd88 and cd40 costimulatory domains
|
|
US12157760B2
(en)
|
2018-05-23 |
2024-12-03 |
The Broad Institute, Inc. |
Base editors and uses thereof
|
|
WO2019232542A2
(en)
|
2018-06-01 |
2019-12-05 |
Massachusetts Institute Of Technology |
Methods and compositions for detecting and modulating microenvironment gene signatures from the csf of metastasis patients
|
|
KR20190141511A
(ko)
|
2018-06-14 |
2019-12-24 |
주식회사 녹십자랩셀 |
신규 펩티드, 이를 포함하는 키메라 항원 수용체 및 이를 발현하는 면역 세포
|
|
US12036240B2
(en)
|
2018-06-14 |
2024-07-16 |
The Broad Institute, Inc. |
Compositions and methods targeting complement component 3 for inhibiting tumor growth
|
|
US12522807B2
(en)
|
2018-07-09 |
2026-01-13 |
The Broad Institute, Inc. |
RNA programmable epigenetic RNA modifiers and uses thereof
|
|
US20210308267A1
(en)
*
|
2018-08-07 |
2021-10-07 |
Purdue Research Foundation |
Rejuvenation of car t cell
|
|
CN114805356A
(zh)
*
|
2018-08-09 |
2022-07-29 |
中国医学科学院北京协和医院 |
用于控制嵌合抗原受体t细胞激活/抑制的连接臂及其应用
|
|
EP3620464A1
(en)
|
2018-09-10 |
2020-03-11 |
Miltenyi Biotec GmbH |
Car cell having crosslinked disulfide bridge on antigen recognizing moiety
|
|
MX2021003435A
(es)
|
2018-09-28 |
2021-06-15 |
Massachusetts Inst Technology |
Moleculas inmunomoduladoras localizadas en el colageno y metodos de las mismas.
|
|
WO2020072700A1
(en)
|
2018-10-02 |
2020-04-09 |
Dana-Farber Cancer Institute, Inc. |
Hla single allele lines
|
|
US12331320B2
(en)
|
2018-10-10 |
2025-06-17 |
The Research Foundation For The State University Of New York |
Genome edited cancer cell vaccines
|
|
WO2020081730A2
(en)
|
2018-10-16 |
2020-04-23 |
Massachusetts Institute Of Technology |
Methods and compositions for modulating microenvironment
|
|
WO2020092453A1
(en)
|
2018-10-29 |
2020-05-07 |
The Broad Institute, Inc. |
Nucleobase editors comprising geocas9 and uses thereof
|
|
WO2020131586A2
(en)
|
2018-12-17 |
2020-06-25 |
The Broad Institute, Inc. |
Methods for identifying neoantigens
|
|
US11739156B2
(en)
|
2019-01-06 |
2023-08-29 |
The Broad Institute, Inc. Massachusetts Institute of Technology |
Methods and compositions for overcoming immunosuppression
|
|
WO2020154500A1
(en)
|
2019-01-23 |
2020-07-30 |
The Broad Institute, Inc. |
Supernegatively charged proteins and uses thereof
|
|
KR20210118945A
(ko)
|
2019-02-15 |
2021-10-01 |
유니버시티 오브 써던 캘리포니아 |
Lym-1 및 lym-2 항체 조성물 및 개선된 car 구성물
|
|
US20220154282A1
(en)
|
2019-03-12 |
2022-05-19 |
The Broad Institute, Inc. |
Detection means, compositions and methods for modulating synovial sarcoma cells
|
|
WO2020191079A1
(en)
|
2019-03-18 |
2020-09-24 |
The Broad Institute, Inc. |
Compositions and methods for modulating metabolic regulators of t cell pathogenicity
|
|
MX2021011426A
(es)
|
2019-03-19 |
2022-03-11 |
Broad Inst Inc |
Metodos y composiciones para editar secuencias de nucleótidos.
|
|
EP3941511A2
(en)
|
2019-03-20 |
2022-01-26 |
Massachusetts Institute of Technology |
Uses of amphiphiles in immune cell therapy and compositions therefor
|
|
KR20210148228A
(ko)
*
|
2019-03-27 |
2021-12-07 |
내셔날 리서치 카운실 오브 캐나다 |
항-EGFRvIII 항체 및 그의 항원-결합 단편
|
|
WO2020201527A1
(en)
|
2019-04-04 |
2020-10-08 |
Umc Utrecht Holding B.V. |
Modified immune receptor constructs
|
|
WO2020214842A1
(en)
|
2019-04-17 |
2020-10-22 |
The Broad Institute, Inc. |
Adenine base editors with reduced off-target effects
|
|
WO2020236967A1
(en)
|
2019-05-20 |
2020-11-26 |
The Broad Institute, Inc. |
Random crispr-cas deletion mutant
|
|
WO2020243371A1
(en)
|
2019-05-28 |
2020-12-03 |
Massachusetts Institute Of Technology |
Methods and compositions for modulating immune responses
|
|
AU2020282791A1
(en)
|
2019-05-31 |
2021-12-09 |
ALX Oncology Inc. |
Methods of treating cancer with SIRP alpha Fc fusion in combination with an immune checkpoint inhibitor
|
|
US11642409B2
(en)
|
2019-06-26 |
2023-05-09 |
Massachusetts Insttute of Technology |
Immunomodulatory fusion protein-metal hydroxide complexes and methods thereof
|
|
US20220282333A1
(en)
|
2019-08-13 |
2022-09-08 |
The General Hospital Corporation |
Methods for predicting outcomes of checkpoint inhibition and treatment thereof
|
|
US12421557B2
(en)
|
2019-08-16 |
2025-09-23 |
The Broad Institute, Inc. |
Methods for predicting outcomes and treating colorectal cancer using a cell atlas
|
|
JP2022546282A
(ja)
|
2019-08-18 |
2022-11-04 |
キメラ・バイオエンジニアリング，インコーポレーテッド |
Ｇｏｌｄ制御導入遺伝子による併用療法
|
|
US20220298501A1
(en)
|
2019-08-30 |
2022-09-22 |
The Broad Institute, Inc. |
Crispr-associated mu transposase systems
|
|
EP4028413A1
(en)
|
2019-09-10 |
2022-07-20 |
Obsidian Therapeutics, Inc. |
Ca2-il15 fusion proteins for tunable regulation
|
|
WO2021061648A1
(en)
|
2019-09-23 |
2021-04-01 |
Massachusetts Institute Of Technology |
Methods and compositions for stimulation of endogenous t cell responses
|
|
US12297426B2
(en)
|
2019-10-01 |
2025-05-13 |
The Broad Institute, Inc. |
DNA damage response signature guided rational design of CRISPR-based systems and therapies
|
|
US12394502B2
(en)
|
2019-10-02 |
2025-08-19 |
The General Hospital Corporation |
Method for predicting HLA-binding peptides using protein structural features
|
|
US12195725B2
(en)
|
2019-10-03 |
2025-01-14 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for modulating and detecting tissue specific TH17 cell pathogenicity
|
|
US11981922B2
(en)
|
2019-10-03 |
2024-05-14 |
Dana-Farber Cancer Institute, Inc. |
Methods and compositions for the modulation of cell interactions and signaling in the tumor microenvironment
|
|
US11793787B2
(en)
|
2019-10-07 |
2023-10-24 |
The Broad Institute, Inc. |
Methods and compositions for enhancing anti-tumor immunity by targeting steroidogenesis
|
|
US12435330B2
(en)
|
2019-10-10 |
2025-10-07 |
The Broad Institute, Inc. |
Methods and compositions for prime editing RNA
|
|
US11844800B2
(en)
|
2019-10-30 |
2023-12-19 |
Massachusetts Institute Of Technology |
Methods and compositions for predicting and preventing relapse of acute lymphoblastic leukemia
|
|
BR112022008817A2
(pt)
|
2019-11-27 |
2022-07-26 |
Alx Oncology Inc |
Terapias combinadas para tratamento de câncer
|
|
US12165747B2
(en)
|
2020-01-23 |
2024-12-10 |
The Broad Institute, Inc. |
Molecular spatial mapping of metastatic tumor microenvironment
|
|
EP4100428A4
(en)
|
2020-02-04 |
2024-03-06 |
Seattle Children's Hospital (DBA Seattle Children's Research Institute) |
CHIMERIC ANTI-DINITROPHENOL ANTIGEN RECEPTORS
|
|
EP3878464A1
(en)
|
2020-03-09 |
2021-09-15 |
Miltenyi Biotec B.V. & Co. KG |
Use of a car cell having crosslinked disulfide bridge on antigen recognizing moiety for targeting cancer cells
|
|
EP3881866A1
(en)
*
|
2020-03-16 |
2021-09-22 |
GEMoaB GmbH |
A targeting module comprising pd-l1 and/or pd-l2 for use in a method for stimulating a chimeric antigen receptor mediated response in a mammal
|
|
KR102502287B1
(ko)
*
|
2020-04-17 |
2023-02-22 |
앱클론(주) |
항-her2 어피바디 및 이를 스위치 분자로 이용하는 스위처블 키메라 항원 수용체
|
|
WO2021212069A1
(en)
|
2020-04-17 |
2021-10-21 |
City Of Hope |
Flt3-targeted chimeric antigen receptor modified cells for treatment of flt3-positive malignancies
|
|
WO2021226558A1
(en)
|
2020-05-08 |
2021-11-11 |
The Broad Institute, Inc. |
Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence
|
|
CN115715295A
(zh)
*
|
2020-05-27 |
2023-02-24 |
安逊生物科学股份有限公司 |
将car t细胞重新定向到感兴趣的抗原的衔接分子
|
|
WO2021246283A1
(ja)
|
2020-06-03 |
2021-12-09 |
京セラ株式会社 |
切削インサート、切削工具及び切削加工物の製造方法
|
|
CN116635519A
(zh)
*
|
2020-11-26 |
2023-08-22 |
上海医药集团生物治疗技术有限公司 |
一种经修饰的免疫细胞及其应用
|
|
CN116635064A
(zh)
|
2020-12-18 |
2023-08-22 |
世纪治疗股份有限公司 |
具有适应性受体特异性的嵌合抗原受体系统
|
|
JP2024520902A
(ja)
|
2021-05-13 |
2024-05-27 |
エーエルエックス オンコロジー インコーポレイテッド |
がんを治療するための併用療法
|
|
US12576135B2
(en)
|
2021-09-29 |
2026-03-17 |
Chimera Bioengineering, Inc. |
Compositions and methods for anti-TnMUC1 gold CAR t-cells
|
|
EP4176895A1
(en)
|
2021-11-08 |
2023-05-10 |
AvenCell Europe GmbH |
Targeting modules against il13ra2 or her2 for use in combination with a chimeric antigen receptor
|
|
JP2025500766A
(ja)
*
|
2021-12-07 |
2025-01-15 |
ザ スクリプス リサーチ インスティテュート |
ヒトの癌を治療するためのｓｗｉｔｃｈａｂｌｅ ＣＡＲ－Ｔ療法
|
|
EP4525899A1
(en)
|
2022-05-17 |
2025-03-26 |
Umoja Biopharma, Inc. |
Manufacturing viral particles
|
|
EP4342907A1
(en)
*
|
2022-09-21 |
2024-03-27 |
AvenCell Europe GmbH |
Switchable chimeric antigen receptors and their use
|
|
EP4598949A1
(en)
|
2022-10-07 |
2025-08-13 |
The General Hospital Corporation |
Methods and compositions for high-throughput discovery of peptide-mhc targeting binding proteins
|
|
TW202434735A
(zh)
|
2022-11-04 |
2024-09-01 |
美商烏莫賈生物製藥股份有限公司 |
展示黏著分子融合的顆粒
|
|
WO2024124044A1
(en)
|
2022-12-07 |
2024-06-13 |
The Brigham And Women’S Hospital, Inc. |
Compositions and methods targeting sat1 for enhancing anti¬ tumor immunity during tumor progression
|
|
EP4713439A1
(en)
*
|
2023-05-19 |
2026-03-25 |
Seoul National University R&DB Foundation |
Safety control of switchable chimeric antigen receptor t cells using dose-adjustable adaptors
|
|
CN116655804A
(zh)
*
|
2023-05-24 |
2023-08-29 |
郑州大学 |
一种用于激活嵌合抗原受体效应细胞的中间模块分子及其应用
|
|
WO2025059533A1
(en)
|
2023-09-13 |
2025-03-20 |
The Broad Institute, Inc. |
Crispr enzymes and systems
|
|
WO2025097055A2
(en)
|
2023-11-02 |
2025-05-08 |
The Broad Institute, Inc. |
Compositions and methods of use of t cells in immunotherapy
|
|
WO2025117544A1
(en)
|
2023-11-29 |
2025-06-05 |
The Broad Institute, Inc. |
Engineered omega guide molecule and iscb compositions, systems, and methods of use thereof
|
|
WO2025231174A1
(en)
|
2024-04-30 |
2025-11-06 |
Umoja Biopharma, Inc. |
Manufacturing viral particles
|
|
WO2025245374A1
(en)
*
|
2024-05-23 |
2025-11-27 |
The Nemours Foundation |
Peptidic chimeric antigen receptor effector cell adapters and uses thereof
|
|
NL2037809B1
(en)
|
2024-05-29 |
2025-12-12 |
Cell Control Biotherapeutics Inc |
Loop reinforcement expression system for improved cell therapy products
|